Liraglutide
First-generation GLP-1 receptor agonist with established clinical efficacy. Acylated peptide with albumin binding for extended half-life, approved for daily administration in diabetes and obesity treatment.
Liraglutide is a 31-amino acid synthetic peptide analog of human glucagon-like peptide-1 (GLP-1) with 97% amino acid sequence homology to endogenous human GLP-1(7-37). It is a long-acting GLP-1 receptor agonist featuring a unique C16 fatty acid (palmitic acid) side chain conjugated to Lys26 via a glutamic acid spacer, enabling prolonged half-life through albumin binding. Liraglutide is the first acylated GLP-1 analog to achieve once-daily dosing, establishing the foundational design principle for modern GLP-1 therapeutics.
| Parameter | Specification |
| CAS | 204656-20-2 |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Type 2 diabetes, obesity, cardiovascular protection |
| CAS | 204656-20-2 |
|---|---|
| Applications |
Related products
-
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog -
Dulaglutide
CAS: 923950-08-7 -
Survodutide
CAS: 2805997-46-8Applications: Liver Fat, NASH, obesity management, Type 2 diabetes -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes